GRAIL, LLC

Yahoo Finance • 5 days ago

GRAIL Gains Momentum Post-IPO Amid Strong Sales, Partnerships, and Executive Share Activity

GRAIL, Inc. (NASDAQ:GRAL) is one of the 11 Best Performing IPOs in the Last 2 Years. Major sales by top executives at the company follow a strong positive second quarter.GRAIL Gains Momentum Post-IPO Amid Strong Sales, Partnerships, and E... Full story

Yahoo Finance • last month

GRAIL shares validate InvestingPro's overvalued call with 41% decline

In February 2025, InvestingPro’s Fair Value model identified (NASDAQ:GRAL) as significantly overvalued at $55.02. Six months later, this analysis has proven remarkably accurate, with the stock declining 41% to $34.24, demonstrating the pow... Full story

Yahoo Finance • last month

Grail updates 2025 cash burn guidance to $310M amid rising Galleri test adoption and expanded partnerships

Earnings Call Insights: GRAIL, Inc. (GRAL) Q2 2025 MANAGEMENT VIEW * CEO Robert P. Ragusa reported continued strong commercial momentum, highlighting that "Galleri test orders continue to grow at a strong clip with more than 45,000 Gal... Full story

Yahoo Finance • last month

GRAIL INC (NASDAQ:GRAL) Reports Mixed Q2 2025 Earnings: Revenue Misses, Loss Narrows

GRAIL INC (NASDAQ:GRAL [https://www.chartmill.com/stock/quote/GRAL/profile]) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. The company, which focuses on early cancer detec... Full story

Yahoo Finance • 3 months ago

Grail (GRAL) PT Hiked to $38 at Morgan Stanley amid ‘Equal Weight’ Stance

Grail, Inc. (NASDAQ:GRAL) is one of the 15 successful spin-off companies. On June 25, Morgan Stanley reiterated an ‘Equal Weight’ on the stock. However, the investment bank raised its price target to $38 from $20. The adjustment is in resp... Full story

Yahoo Finance • 6 months ago

Jim Cramer Likes GRAIL, Inc. (GRAL) Despite Losses – Great Science, Risky Bet!

We recently published a list of Jim Cramer Put These 16 Stocks Under a Microscope. In this article, we are going to take a look at where GRAIL, Inc. (NASDAQ:GRAL) stands against other stocks that Jim Cramer put under a microscope. On Thur... Full story

Yahoo Finance • 7 months ago

GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System

GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. and SECAUCUS, N.J., Feb. 12, 2025 /PRNews... Full story